Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19)Sources of Support None.
The Spanish influenza pandemic of 1918 globally claimed between 50 and 100 million lives. In India, it was referred to as “The Bombay Fever” and accounted for a fifth of the global death toll. The current outbreak of the novel coronavirus (2019-nCoV), a new human-infecting β-coronavirus, has clearly demonstrated that the size of an organism does not reflect on its ability to affect an entire human population. 2019-nCOV, first detected in December 2019 in Wuhan, China, spread rapidly globally. Disease in humans ranged from flulike symptoms to severe acute hypoxic respiratory failure. The virus appears closely related to two bat-derived severe acute respiratory syndromes (SARS) coronaviruses. Although bats were likely the original host, animals sold at the Huanan seafood market in Wuhan might have been the intermediate host that enabled the emergence of the virus in humans. Under the electron microscope, the SARS-CoV-2 virus grips its receptor tighter than the virus behind the SARS outbreak in 2003 to 2004. The viral particle docks onto the angiotensin-converting enzyme 2 (ACE2) receptor and initiates viral entry. This review discusses the various aspects of the SARS-CoV-2 virus, its structure, pathophysiology, mechanism of interaction with human cells, virulence factors, and drugs involved in the treatment of the disease.
06 November 2020 (online)
© 2020. Official Publication of The Simulation Society (TSS), accredited by International Society of Cardiovascular Ultrasound ISCU. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Shi Y, Wang G, Cai XP. et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21 (05) 343-360
- 2 DownToEarth. Between 1918–19 Spanish flu and COVID-19, not much has changed. https://www.downtoearth.org.in/blog/governance/between-1918-19-spanish-flu-and-covid-19-not-much-has-changed-71425
- 3 Liang W, Liang H, Ou L, et al; China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020
- 4 Yadav PD, Potdar VA, Choudhary ML. et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res 2020; 151 (2 & 3) 200-209
- 5 Kirchdoerfer RN, Cottrell CA, Wang N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 2016; 531 (7592) 118-121
- 6 Walls AC, Tortorici MA, Bosch BJ. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 2016; 531 (7592) 114-117
- 7 Beniac DR, Andonov A, Grudeski E, Booth TF. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol 2006; 13 (08) 751-752
- 8 Li F, Berardi M, Li W, Farzan M, Dormitzer PR, Harrison SC. Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J Virol 2006; 80 (14) 6794-6800
- 9 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367 (6485) 1444-1448
- 10 Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 2015; 89 (04) 1954-1964
- 11 Li F. Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J Virol 2008; 82 (14) 6984-6991
- 12 Wu K, Chen L, Peng G. et al. A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses. J Virol 2011; 85 (11) 5331-5337
- 13 Wu K, Peng G, Wilken M, Geraghty RJ, Li F. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem 2012; 287 (12) 8904-8911
- 14 Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol 2020; 17 (05) 536-538
- 15 Lan J, Ge J, Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581 (7807) 215-220
- 16 Wang Q, Zhang Y, Wu L. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020; 181 (04) 894-904.e9
- 17 Srinivasan S, Cui H, Gao Z. et al. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses 2020; 12 (04) E360
- 18 Brielle ES, Schneidman-Duhovny D, Linial M. The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor. Viruses 2020; 12 (05) E497
- 19 Perico L, Benigni A, Remuzzi G. Reply to the Comment by Dr. Cure on “Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade.”. Nephron 2020; 144 (05) 253-254
- 20 Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron 2020
- 21 Javanmard SH, Heshmat-Ghahdarijani K, Vaseghi G. Angiotensinconverting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: a paradox. Infect Control Hosp Epidemiol 2020; (e-pub ahead of print) DOI: 10.1017/ice.2020.195.
- 22 Bean D, Kraljevic Z, Searle T. et al. Treatment with ACE-inhibitors is associated with less severe SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. medRxiv 2020; (e-pub ahead of print) DOI: 10.1101/2020.04.07.20056788.
- 23 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020
- 24 Liu L, Wei Q, Lin Q. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4 (04) e123158
- 25 Stebbing J, Phelan A, Griffin I. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20 (04) 400-402
- 26 Montealegre-Gomez G, Garavito E, Gomez-Lopez A, Rojas-Villarraga A, Parra-Medina R. Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients [in Spanish]. Reumatol Clin 2020; (e-pub ahead of print) DOI: 10.1016/j.reuma.2020.05.001.
- 27 Chinese Clinical Trial Registry. Available at: http://www.chictr.org.cn/searchprojen.aspx.
- 28 Dimopoulos G, de Mast Q, Markou N. et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe 2020; 28 (01) 117-123.e1
- 29 Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect 2020; 81 (01) 1-9
- 30 Tu WJ, Cao J, Yu L, Hu X, Liu Q. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. Intensive Care Med 2020; 46 (06) 1117-1120
- 31 LinksMedicus - Free Medical News & Perspectives. COVID-19 Updates. Available at: https://www.linksmedicus.com/news/coronavirus-disease-covid-19-updates/.
- 32 Zhang Y, Yu L, Tang L. et al. A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification. Syst Eng 2020; (e-pub ahead of print) DOI: 10.1016/j.eng.2020.03.006.
- 33 Ma J, Xia P, Zhou Y. et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol 2020; 214: 108408
- 34 Rothe C, Schunk M, Sothmann P. et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020; 382 (10) 970-971
- 35 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223) 507-513
- 36 COVID-19 disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. Available at: https://www.researchgate.net/publication/339748594_COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin.
- 37 Wenzhong L, Hualan L. COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173
- 38 Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020; 80 (06) e14-e18
- 39 Lu G, Wang J. Dynamic changes in routine blood parameters of a severe COVID-19 case. Clin Chim Acta 2020; 508: 98-102
- 40 Terpos E, Ntanasis-Stathopoulos I, Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95 (07) 834-847
- 41 Spiezia L, Boscolo A, Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120 (06) 998-1000
- 42 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135 (23) 2033-2040
- 43 Wichmann D, Sperhake JP, Lutgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; (e-pub ahead of print) DOI: 10.7326/M20-2003.
- 44 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383 (02) 120-128
- 45 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
- 46 Klok FA, Kruip MJHA, van der Meer NJM. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191: 148-150
- 47 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382 (17) e38
- 48 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
- 49 Thachil J, Tang N, Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18 (05) 1023-1026
- 50 Kupferschmidt K. WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020
- 51 Boulware DR, Pullen MF, Bangdiwala AS. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2016638.
- 52 Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS. et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax. Antimicrob Agents Chemother 2009; 53 (04) 1468-1475
- 53 Liu J, Cao R, Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6 (01) 16
- 54 Pastick KA, Okafor EC, Wang F. et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020; 7 (04) a130
- 55 Million M, Lagier JC, Gautret P. et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020; (e-pub ahead of print) DOI: 10.1016/j.tmaid.2020.101738.
- 56 Andreani J, Le Bideau M, Duflot I. et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog 2020; 145: 104228
- 57 Chorin E, Wadhwani L, Magnani S. et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm 2020; (e-pub ahead of print) DOI: 10.1016/j.hrthm.2020.05.014.
- 58 Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295 (15) 4773-4779
- 59 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2007764.
- 60 Grein J, Ohmagari N, Shin D. et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24) 2327-2336
- 61 Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 2018; 153: 85-94
- 62 Lê MP, Peiffer-Smadja N, Guedj J. et al. C-20–15 DisCoVeRy French Steering Committee. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother 2020; (e-pub ahead of print) DOI: 10.1093/jac/dkaa191.
- 63 ClinicalTrials. Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy). Available at: https://clinicaltrials.gov/ct2/show/NCT04315948.
- 64 ClinicalTrials. Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO). Available at: https://clinicaltrials.gov/ct2/show/NCT04330690?cond=solidarity+trial&draw=2&rank=1.
- 65 Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 2016; 21 (05) 455-459
- 66 Arabi YM, Alothman A, Balkhy HH. et al. And the MIRACLE trial group. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018; 19 (01) 81
- 67 Cao B, Wang Y, Wen D. et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 (19) 1787-1799
- 68 Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130 (04) 1545-1548
- 69 Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience 2020; 14: 1023
- 70 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223) 473-475
- 71 Alhazzani W, Møller MH, Arabi YM. et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020; 46 (05) 854-887
- 72 Fadel R, Morrison AR, Vahia A. et al. Henry Ford COVID-19 Management Task Force. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020; ciaa601
- 73 Zhu FC, Li YH, Guan XH. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395 (10240) 1845-1854
- 74 Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382 (21) 1969-1973
- 75 Lv H, Wu NC, Mok CKP. COVID-19 vaccines: knowing the unknown. Eur J Immunol 2020; 50 (07) 939-943
- 76 Caddy S. Developing a vaccine for Covid-19. BMJ 2020; 369: m1790
- 77 Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science 2020; 368 (6494) 948-950
- 78 Graham BS. Rapid COVID-19 vaccine development. Science 2020; 368 (6494) 945-946
- 79 Thanh Le T, Andreadakis Z, Kumar A. et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19 (05) 305-306